Eli Lilly and Company announced on Thursday that it has entered into a definitive agreement to acquire AtaiBeckley Inc., a clinical-stage biopharmaceutical company focused on developing novel treatments for mental health disorders. The deal should bolster Lilly’s neuroscience pipeline with promising therapies aimed at treatment-resistant depression and other challenging conditions.
AtaiBeckley is developing rapid-acting neuroplastogens, including its lead candidate BPL-003, a synthetic form of 5-MeO-DMT administered as an intranasal spray. The compound has shown promise for providing long-lasting relief from depressive symptoms after a single in-clinic treatment lasting about two hours. It has already been granted Breakthrough Therapy Designation by the Food and Drug Administration and is in Phase 3 development.
Treatment-resistant depression is depression that does not respond to multiple treatments. “Millions of people are still seeking relief and are in desperate need of a therapy that works,” said Carole Ho, executive vice president and president, Lilly Neuroscience. “Moving forward with AtaiBeckley’s investigational therapies gives us a real opportunity to change that.
Lilly will pay $6.75 per share in cash at closing and additional contingent value rights of up to $2.50 per share based on future development and regulatory milestones. The upfront consideration values AtaiBeckley at approximately $2.8 billion, with potential additional value of approximately $1.0 billion from the CVRs.
The deal is part of a growing interest in the industry in new mechanisms for treating mental health. But AtaiBeckley is pursuing a different avenue, trying to restore synaptic plasticity in the brain, rather than just modulating levels of neurotransmitters like traditional antidepressants do. This novel mechanism may provide hope for millions of Americans who do not get adequate relief from existing options.
“We’re trying to show across our portfolio that psychiatric illness is treatable at the biological root, not just the symptoms,” said Srinivas Rao, co-founder and chief executive officer of AtaiBeckley.
The transaction is expected to close in the third quarter, pending shareholder approval and customary regulatory conditions. The deal has been approved by both companies’ boards and key shareholders have agreed to support it.
The move is part of Lilly’s strategy to expand in high-need therapeutic areas through both internal research and strategic acquisitions. Mental health continues to be one of the greatest public health challenges. A significant number of patients with treatment-resistant depression, who did not respond to multiple therapies.
The acquisition could speed up the development time for these promising new compounds and inject much-needed innovation into a field that has seen relatively few breakthroughs in recent decades. If larger trials prove it is safe and effective, there are potential benefits for patients, clinicians and the wider healthcare system.
As the deal progresses, the industry will be closely watching how Lilly integrates AtaiBeckley’s pipeline and moves those programs toward potential approval. For millions living with hard-to-treat depression, the hope is that this partnership will bring meaningful new options in the years ahead.
